HC Wainwright Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine (NASDAQ:IRON) had its price target raised by equities researchers at HC Wainwright from $120.00 to $127.00 in a report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s price objective suggests a potential upside of 60.94% from the stock’s current price. HC Wainwright also issued estimates for Disc Medicine’s Q1 2027 earnings at ($1.53) EPS.

Other equities research analysts have also issued research reports about the stock. Wedbush upped their price objective on shares of Disc Medicine from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, October 19th. Truist Financial boosted their target price on shares of Disc Medicine from $83.00 to $115.00 and gave the company a “buy” rating in a report on Monday, October 19th. Wells Fargo & Company boosted their target price on shares of Disc Medicine from $86.00 to $124.00 and gave the company an “overweight” rating in a report on Tuesday, October 20th. Wall Street Zen cut shares of Disc Medicine from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Finally, Morgan Stanley raised their price target on shares of Disc Medicine from $90.00 to $92.00 and gave the stock an “overweight” rating in a report on Tuesday, October 20th. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and a consensus price target of $123.40.

Disc Medicine Price Performance

NASDAQ:IRON opened at $78.91 on Friday. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. Disc Medicine has a 52 week low of $40.00 and a 52 week high of $99.50. The stock’s 50-day moving average price is $71.21 and its 200-day moving average price is $70.93. The stock has a market capitalization of $3.03 billion, a PE ratio of -12.45 and a beta of 0.96.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.63) by $0.10. As a group, equities analysts expect that Disc Medicine will post -6.54 EPS for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In related news, Director Kevin Bitterman sold 49,164 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $80.17, for a total value of $3,941,477.88. Following the completion of the sale, the director owned 13,499 shares in the company, valued at $1,082,214.83. This trade represents a 78.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John D. Quisel sold 33,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the sale, the chief executive officer directly owned 226,064 shares in the company, valued at approximately $17,892,965.60. This represents a 12.74% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 168,046 shares of company stock worth $13,191,034. 3.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On Disc Medicine

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Aberdeen Group plc lifted its holdings in Disc Medicine by 36.4% in the third quarter. Aberdeen Group plc now owns 597,841 shares of the company’s stock valued at $39,135,000 after buying an additional 159,667 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Disc Medicine by 142.2% during the third quarter. Russell Investments Group Ltd. now owns 19,576 shares of the company’s stock worth $1,281,000 after purchasing an additional 11,493 shares during the period. Jefferies Financial Group Inc. acquired a new stake in shares of Disc Medicine during the third quarter worth $707,000. AlphaCentric Advisors LLC increased its holdings in Disc Medicine by 77.7% in the third quarter. AlphaCentric Advisors LLC now owns 7,161 shares of the company’s stock valued at $469,000 after purchasing an additional 3,131 shares during the last quarter. Finally, Alps Advisors Inc. increased its holdings in Disc Medicine by 31.9% in the third quarter. Alps Advisors Inc. now owns 50,856 shares of the company’s stock valued at $3,329,000 after purchasing an additional 12,291 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.